Kurzfassung

LUX-Lung 3; a randomised, open -label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation

Bis 9/2011 Projektleitung Dr Martin Sebastian